What is BIIB stock price today?

BIIB (Biogen Inc) stock is trading at $191.82 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is BIIB stock going up or down today?

BIIB stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy BIIB stock now?

The decision to buy BIIB depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is BIIB a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for BIIB based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is BIIB stock overvalued or undervalued?

BIIB currently trades at a P/E ratio of 21.82 relative to earnings. Our DCF calculator provides intrinsic value estimates to help determine if BIIB is fairly priced.

What is BIIB's P/E ratio?

BIIB has a price-to-earnings (P/E) ratio of 21.82, which measures how much investors are willing to pay per dollar of earnings. Compare this to industry peers and historical averages for context.

What is BIIB's market cap?

BIIB (Biogen Inc) has a market capitalization of $28.15 billion, making it a mid-cap stock.

What is BIIB's price to book ratio?

BIIB trades at a price-to-book (P/B) ratio of 1.51, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does BIIB pay dividends?

BIIB does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is BIIB's dividend yield?

BIIB does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is BIIB stock a good long-term investment?

BIIB's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is BIIB's revenue growth rate?

BIIB has shown revenue growth of -0.1% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Yes, BIIB is profitable with a profit margin of 0.1%. This indicates the company generates 0.1 cents of profit for every dollar of revenue.

What are the risks of investing in BIIB?

Key risks for BIIB include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does BIIB compare to its competitors?

Compare BIIB to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize BIIB's performance and positioning.

What is BIIB's stock price target for 2026?

Our AI model provides price targets for BIIB based on fundamental analysis: Bull case $249.37 (+30%), Base case $220.59 (+15%), Bear case $172.64 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about BIIB?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for BIIB. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is BIIB's next earnings report?

BIIB reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

BIIB - Biogen Inc

NYSE * Health Care * Pharmaceuticals

$191.82

+$3.80 (+2.02%)

About Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

BIIB Key Statistics

Market Cap

$28.15B

P/E Ratio

21.82

P/B Ratio

1.51

EPS

$8.79

Revenue Growth

-0.1%

Profit Margin

0.1%

Employees

7,500

How BIIB Compares to Peers

BIIB has the lowest P/E ratio in Pharmaceuticals, suggesting it may be the most undervalued

BIIB has the highest profit margins in Pharmaceuticals

BIIB is the smallest among peers, which may offer higher growth potential

P/E Rank

of 2

Margin Rank

of 2

Growth Rank

of 2

Size Rank

of 2

Company	Market Cap	P/E	Growth	Margin	Compare
BIIB(This stock)	$28.15B	21.8	-0%	0.1%	-
AMZNAmazon Com	$2.23T	29.0	0%	0.1%	vs AMZN

Biogen Inc Company Information

Headquarters: Massachusetts; U.S.A
Website: www.biogen.com
Sector: Health Care
Industry: Pharmaceuticals

BIIB - Biogen Inc

About Biogen Inc

BIIB Key Statistics

How BIIB Compares to Peers

Biogen Inc Company Information

BIIB Lician Score

BIIB Financial Snowflake

Upcoming Events for BIIB